Biocytogen Pharms (Beijing)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH003, a humanized IgG2 agonistic monoclonal antibody targeting the CD40, a costimulatory protein found on antigen-presenting cells; and YH001, a humanized anti-CTLA-4, IgG1 monoclonal antibody. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human OX40 receptor; H004, a humanized IgG1 anti-4-1BB Agonists; YH005, an anti-Claudin 18.2 antibody; and YH008, an anti-PD-1/CD 40 bi-specific antibody for the treatment of solid tumors. In addition, its pre-clinical products include YH012 and YH013 for the treatment of solid tumor; YH015, a human IgG1 antagonistic monoclonal antibody to treat CD40; YH016 to treat oncology; and YH017 for the treatment of autoimmunity. Further, the company develops various products for the treatment of oncology, autoimmune, inflammatory, metabolic, and other diseases. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was incorporated in 2009 and is based in Beijing, China. Show More...